<DOC>
	<DOCNO>NCT00003730</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Randomized clinical trial study effectiveness vinorelbine plus fluorouracil treat woman metastatic breast cancer previously treat least one regimen chemotherapy .</brief_summary>
	<brief_title>Vinorelbine Plus Fluorouracil Treating Women With Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine least toxic time vinorelbine administration combine chronomodulated fluorouracil woman previously treat metastatic breast cancer . - Determine toxic effect dose intensity drug woman . OUTLINE : This randomize , multicenter study . Patients stratify accord prior chemotherapy ( second line v third line ) participate center . Patients randomize 1 8 vinorelbine dose time ( 0000 , 0300 , 0600 , 0900 , 1200 , 1500 , 1800 , 2100 ) . Patients receive vinorelbine IV 20 minute day 1 6 fluorouracil IV 12 hour accord chronomodulated delivery rate ( 2200 1000 maximum dose 0400 ) day 1-4 . Treatment repeat every 3 week least 3 course absence unacceptable toxicity . Patients follow 30 day . PROJECTED ACCRUAL : A minimum 80 patient ( 10 per dose time ) accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic breast cancer At least 1 line prior chemotherapy metastatic disease ( adjuvant neoadjuvant chemotherapy consider first line complete less one year prior palliative chemotherapy ) No cerebral metastasis Hormonal receptor status : Not specify PATIENT CHARACTERISTICS : Age : Not specify Sex : Female Menopausal status : Not specify Performance status : WHO 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm ^3 Hepatic : Bilirubin great 2.5 time upper limit normal ( ULN ) AST/ALT great 2.5 time ULN Renal : Creatinine great 1.58 mg/dL Cardiovascular : No clinically significant cardiac insufficiency ischemic disease Pulmonary : No bronchoconstriction pulmonary lymphangitis Other : No serious chronic disease No bowel obstruction Not pregnant nursing PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent immunotherapy No concurrent prophylactic growth factor Chemotherapy : See Disease Characteristics At least 4 week since prior chemotherapy No prior highdose chemotherapy No concurrent chemotherapy Endocrine therapy : No concurrent hormonal therapy No concurrent steroid therapy except emergency Radiotherapy : At least 4 week since prior radiotherapy ( primary tumor axillary mammary chain treatment ) No concurrent radiotherapy Surgery : Not specify Other : No concurrent antitumor therapy</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>